A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully. For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users. “If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said. Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market. “It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.” And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021. For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).

Share:
More In Business
Markets Skyrocket Post 2024 Election
With the election behind us, many are wondering what the next four years look like for the US economy. Drew Pettit, from Citi Group joins Cheddar to discuss.
Could Millennials be Saving Too Much?
An interesting savings trend has popped up among Millennials. Could they be saving TOO much money? Callie Cox at Ritholtz Wealth Management explains.
Why Home Sales Are Worse Than Ever
Gina Heeb, finance reporter at The Wall Street Journal, joins us to discuss the current state of the real estate market and when things may turn around. Watch!
Load More